NASDAQ:EOLS

Evolus Stock Forecast, Price & News

$10.82
+0.01 (+0.09 %)
(As of 07/30/2021 04:41 PM ET)
Add
Compare
Today's Range
$10.61
$11.11
50-Day Range
$9.48
$13.96
52-Week Range
$2.85
$17.38
Volume286,047 shs
Average Volume347,417 shs
Market Capitalization$585.58 million
P/E RatioN/A
Dividend YieldN/A
Beta2.35
30 days | 90 days | 365 days | Advanced Chart
Receive EOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.


Evolus logo

About Evolus

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.90 out of 5 stars

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Evolus (NASDAQ:EOLS) Frequently Asked Questions

Is Evolus a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Evolus stock.
View analyst ratings for Evolus
or view top-rated stocks.

What stocks does MarketBeat like better than Evolus?

Wall Street analysts have given Evolus a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Evolus wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Evolus' next earnings date?

Evolus is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Evolus
.

How can I listen to Evolus' earnings call?

Evolus will be holding an earnings conference call on Wednesday, August 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) issued its quarterly earnings data on Wednesday, May, 12th. The company reported $0.16 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.58) by $0.74. The firm had revenue of $12.24 million for the quarter, compared to analyst estimates of $11.42 million. Evolus had a negative trailing twelve-month return on equity of 736.81% and a negative net margin of 234.87%.
View Evolus' earnings history
.

How has Evolus' stock been impacted by COVID-19?

Evolus' stock was trading at $5.91 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EOLS shares have increased by 83.1% and is now trading at $10.82.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for EOLS?

8 analysts have issued 1 year price objectives for Evolus' stock. Their forecasts range from $7.00 to $25.00. On average, they expect Evolus' share price to reach $16.38 in the next year. This suggests a possible upside of 51.3% from the stock's current price.
View analysts' price targets for Evolus
or view top-rated stocks among Wall Street analysts.

Who are Evolus' key executives?

Evolus' management team includes the following people:
  • Mr. David Moatazedi, Pres, CEO & Director (Age 43, Pay $1.25M)
  • Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 63, Pay $633.18k)
  • Dr. Rui Avelar Dip.SportMed, M.D., C.CFP, Chief Medical Officer and Head of R&D (Age 59, Pay $631.26k)
  • Mr. Jeffrey J. Plumer, Gen. Counsel
  • Mr. Kurt Knab, VP of Sales
  • Ms. Crystal Muilenburg, Chief Marketing Officer (Age 41)

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus CEO David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among Evolus' employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Evolus' key competitors?

What other stocks do shareholders of Evolus own?

When did Evolus IPO?

(EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Who are Evolus' major shareholders?

Evolus' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (0.08%) and Vanguard Capital Wealth Advisors (0.02%). Company insiders that own Evolus stock include Lauren P Silvernail and Rui Avelar.
View institutional ownership trends for Evolus
.

Which institutional investors are buying Evolus stock?

EOLS stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Capital Wealth Advisors, and Alliancebernstein L.P..
View insider buying and selling activity for Evolus
or or view top insider-buying stocks.

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $10.82.

How much money does Evolus make?

Evolus has a market capitalization of $585.58 million and generates $56.54 million in revenue each year. The company earns $-163,010,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis.

How many employees does Evolus have?

Evolus employs 106 workers across the globe.

What is Evolus' official website?

The official website for Evolus is www.evolus.com.

Where are Evolus' headquarters?

Evolus is headquartered at 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]


This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.